Yang Chunyan, Dai Yanling, Pang Shuhua, Guo Xiaomin
Department of Pharmacy, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China.
Laboratory Department, Chuxiong Medical College, Chuxiong, Yunnan 675000, P.R. China.
Oncol Lett. 2020 Aug;20(2):1922-1930. doi: 10.3892/ol.2020.11719. Epub 2020 Jun 9.
Efficacy of abiraterone combined with flutamide on patients with prostate cancer (PCa) and its effect on levels of miR-493-5p and miR-195-5p contained in serum were investigated. The medical records of 146 PCa patients admitted to Longhua Hospital Shanghai University of Traditional Chinese Medicine from January 2011 to December 2013 were selected. Eighty-four patients were treated with abiraterone combined with flutamide as a study group, 62 patients were treated with abiraterone alone as a control group. The curative effect, adverse reactions, quality of life and five-year overall survival (OS) of the two groups were compared. The serum prostate-specific antigen (PSA) level was measured by radioimmunoassay at 3 days (T1) before treatment, 1 month (T2), 2 months (T3), and 6 months (T4) after treatment, and the relative expression of miR-493-5p and miR-195-5p in serum were detected by qRT-PCR. The total effective rate of the study group was significantly higher than that of the control group (P<0.05). The total incidence of toxic and side effects in the study group was significantly lower than that in the control group (P<0.05). The improvement rate of quality of life in the study group was significantly higher than that in the control group (P<0.05). OS in the study group was significantly higher than that in the control group at 5 years (P<0.05). There was no significant difference in serum PSA level between the two groups at T1 (P>0.05); there was no significant difference in the relative expression of miR-493-5p and miR-195-5p between the two groups at T1 (P>0.05). In conclusion, abiraterone combined with flutamide has better curative effect and lower incidence of adverse reactions in patients with metastatic castration-resistant PCa (CRPC) than abiraterone alone, and can increase the expression levels of miR-493-5p and miR-195-5p in patient serum.
研究了阿比特龙联合氟他胺对前列腺癌（PCa）患者的疗效及其对血清中miR-493-5p和miR-195-5p水平的影响。选取2011年1月至2013年12月上海中医药大学附属龙华医院收治的146例PCa患者的病历资料。84例患者接受阿比特龙联合氟他胺治疗作为研究组，62例患者仅接受阿比特龙治疗作为对照组。比较两组的疗效、不良反应、生活质量和五年总生存率（OS）。在治疗前3天（T1）、治疗后1个月（T2）、2个月（T3）和6个月（T4）采用放射免疫法测定血清前列腺特异性抗原（PSA）水平，采用qRT-PCR检测血清中miR-493-5p和miR-195-5p的相对表达。研究组的总有效率显著高于对照组（P<0.05）。研究组的毒副作用总发生率显著低于对照组（P<0.05）。研究组的生活质量改善率显著高于对照组（P<0.05）。研究组5年的OS显著高于对照组（P<0.05）。两组在T1时血清PSA水平无显著差异（P>0.05）；两组在T1时miR-493-5p和miR-195-5p的相对表达无显著差异（P>0.05）。综上所述，对于转移性去势抵抗性PCa（CRPC）患者，阿比特龙联合氟他胺比单用阿比特龙具有更好的疗效和更低的不良反应发生率，并且可以提高患者血清中miR-493-5p和miR-195-5p的表达水平。
